Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg)
and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA)
axis function as measured by serum cortisol AUC(0-24 hr) in children (>=2 to <12 years old)
with allergic rhinitis (AR).